UK-based clinical-stage biotechnology startup MiroBio has raised USD 97 million (GBP 80 million) in a Series B funding round led by Medicxi, with participation from several other new and existing investors including OrbiMed. Nick Williams of Medicxi and Erez Chimovits of OrbiMed will join MiroBio’s board of directors.
The funds will be used to progress its lead antibody drug candidates, MB272 and MB151 into clinical trials. The MB272 and MB151 candidates are checkpoint receptor agonists for treating autoimmune diseases. The funds will also be directed toward advancing its preclinical pipeline and building out its proprietary I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium) discovery platform.
MiroBio’s I-ReSToRE platform was designed to help discover and develop treatment strategies for autoimmune diseases, based on an atlas of receptor expressions and functions, antibody discovery processes, and advanced bioinformatics. The firm’s technology was built on more than 15 years of checkpoint agonism research at the University of Oxford.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.